Thermo Fisher Scientific reported Q2 2026 revenue of USD 11.99 billion, up 10% year-on-year from USD 10.85 billion, prompting the company to raise its full-year 2026 revenue and earnings guidance.

The company now expects adjusted earnings per share (EPS) of USD 24.93–25.33 for FY26, up from its earlier forecast of USD 24.64–25.12. It also increased its full-year revenue outlook to USD 47.4–48.1 billion, representing annual growth of 6%–8% over 2025.

Thermo Fisher's quarterly performance exceeded market expectations, with EPS of USD 6.03 compared with analysts' consensus estimate of USD 5.71, while revenue also surpassed the estimated USD 11.7 billion.

The strong results lifted investor sentiment, with Thermo Fisher's shares rising 8.7% on the New York Stock Exchange following the earnings announcement.

"Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain," said Marc Casper, Chairman and CEO of Thermo Fisher Scientific.

The company's Laboratory Products and Biopharma Services division remained its largest business segment, generating USD 6.69 billion in revenue, a 12% year-on-year increase, accounting for nearly 56% of total quarterly sales. According to the company, growth was driven by its global research and safety distribution network and clinical research business.

The Life Sciences Solutions and Analytical Instruments businesses contributed 23.5% and 15.4% of total quarterly revenue, respectively.

Meanwhile, Thermo Fisher's Specialty Diagnostics segment generated approximately USD 1.2 billion in revenue during the quarter. Earlier this year, the company agreed to sell its microbiology business—part of the specialty diagnostics portfolio—to private equity firm Astorg in a deal valued at over USD 1 billion, as it continues to streamline its diagnostics portfolio.